Patents by Inventor Steven K. Burke
Steven K. Burke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8377428Abstract: Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent.Type: GrantFiled: April 21, 2009Date of Patent: February 19, 2013Assignee: Genzyme CorporationInventors: John S. Petersen, Steven K. Burke, Stephen Randall Holmes-Farley
-
Publication number: 20100068167Abstract: Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent.Type: ApplicationFiled: April 21, 2009Publication date: March 18, 2010Applicant: GENZYME CORPORATIONInventors: John S. Petersen, Steven K. Burke, Stephen Randall Holmes-Farley
-
Publication number: 20090304623Abstract: A method for reducing serum phosphate in a subject in need thereof comprising administering once per day to said subject a phosphate binder, wherein the phosphate binder has a phosphate binding capacity of at least 52 mmole.Type: ApplicationFiled: May 14, 2009Publication date: December 10, 2009Applicant: GENZYME CORPORATIONInventor: Steven K. Burke
-
Patent number: 7541024Abstract: Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent.Type: GrantFiled: April 17, 2002Date of Patent: June 2, 2009Assignee: Genzyme CorporationInventors: John S. Petersen, Steven K. Burke, Stephen Randall Holmes-Farley
-
Publication number: 20080112918Abstract: A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer, for example, an aliphatic amine polymer. In one embodiment, the polymer binds to uric acid or a precursor thereof. Examples of polymers useful in an embodiment of the invention include sevelamer hydrochloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that binds serum uric acid in a patient.Type: ApplicationFiled: June 18, 2007Publication date: May 15, 2008Inventors: Stephen Randall Holmes-Farley, Steven K. Burke
-
Patent number: 7261880Abstract: The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: where n is a positive integer and each R, independently, is H or a C1–C8 alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.Type: GrantFiled: April 17, 2002Date of Patent: August 28, 2007Assignee: Genzyme CorporationInventors: Steven K. Burke, Joanne M. Donovan
-
Patent number: 7229613Abstract: A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.Type: GrantFiled: April 17, 2002Date of Patent: June 12, 2007Assignee: Genzyme CorporationInventors: Steven K. Burke, Joanne M. Donovan
-
Patent number: 7220406Abstract: Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename Renagel®, is the preferred polymer used in the invention.Type: GrantFiled: October 16, 2003Date of Patent: May 22, 2007Assignee: Genzyme CorporationInventor: Steven K. Burke
-
Publication number: 20040120922Abstract: Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename Renagel®, is the preferred polymer used in the invention.Type: ApplicationFiled: October 16, 2003Publication date: June 24, 2004Applicant: Genzyme CorporationInventor: Steven K. Burke
-
Publication number: 20030086898Abstract: A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymers characterized by a repeat unit having the formula: 1Type: ApplicationFiled: May 29, 2002Publication date: May 8, 2003Applicant: GelTex Pharmaceuticals, Inc.Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, Steven K. Burke, Dennis I. Goldberg
-
Publication number: 20030049226Abstract: The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: 1Type: ApplicationFiled: April 17, 2002Publication date: March 13, 2003Applicant: GelTex Pharmaceuticals, Inc. Waltham, MAInventors: Steven K. Burke, Joanne M. Donovan
-
Publication number: 20030039627Abstract: A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer, for example, an aliphatic amine polymer. In one embodiment, the polymer binds to uric acid or a precursor thereof. Examples of polymers useful in an embodiment of the invention include sevelamer hydrochloride and colesevelam.Type: ApplicationFiled: April 17, 2002Publication date: February 27, 2003Applicant: GelTex Pharmaceutical, Inc.Inventors: Stephen Randall Holmes-Farley, Steven K. Burke
-
Publication number: 20020187120Abstract: A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer; for example, an aliphatic amine polymer. Examples of polymers useful in the invention are sevelamer hydrogen chloride and colesevelam.Type: ApplicationFiled: April 17, 2002Publication date: December 12, 2002Applicant: GelTex Pharmaceutical, Inc.Inventors: Stephen Randall Holmes-Farley, Steven K. Burke
-
Publication number: 20020187121Abstract: A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam.Type: ApplicationFiled: April 17, 2002Publication date: December 12, 2002Applicant: GelTex Pharmaceutical, Inc.Inventor: Steven K. Burke
-
Publication number: 20020168333Abstract: A method is disclosed for improving vascular access in a patient in need thereof by administering to the patient a therapeutically effective amount of at least one amine polymer. Cross-linked polyallylamine polymers are particularly efficacious.Type: ApplicationFiled: April 17, 2002Publication date: November 14, 2002Applicant: GelTex Pharmaceuticals, Inc.Inventor: Steven K. Burke
-
Publication number: 20020159968Abstract: Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent.Type: ApplicationFiled: April 17, 2002Publication date: October 31, 2002Applicant: GelTex pharmaceutical, Inc.Inventors: John S. Petersen, Steven K. Burke, Stephen Randall Holmes-Farley
-
Patent number: 6423754Abstract: A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymer characterized by a repeat unit having the formula: and salts thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.Type: GrantFiled: November 26, 1997Date of Patent: July 23, 2002Assignee: GelTex Pharmaceuticals, Inc.Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III, Steven K. Burke, Dennis I. Goldberg